ID

13712

Descrizione

Telaprevir, Peg-IFN-alfa-2a, and RBV in Treatment-Experienced Black/African American and Non-Black/African American Subjects With Genotype 1 Chronic Hepatitis C; ODM derived from: https://clinicaltrials.gov/show/NCT01467492

collegamento

https://clinicaltrials.gov/show/NCT01467492

Keywords

  1. 29/02/16 29/02/16 -
Caricato su

29 febbraio 2016

DOI

Per favore, per richiedere un accesso.

Licenza

Creative Commons BY 4.0

Commenti del modello :

Puoi commentare il modello dati qui. Tramite i fumetti nei gruppi di articoli e articoli è possibile aggiungere commenti a quelli in modo specifico.

Commenti del gruppo di articoli per :

Commenti dell'articolo per :

Per scaricare i modelli di dati devi essere registrato. Per favore accesso o registrati GRATIS.

Eligibility Hepatitis C NCT01467492

Eligibility Hepatitis C NCT01467492

Inclusion Criteria
Descrizione

Inclusion Criteria

Alias
UMLS CUI
C1512693
participants self-identify as black/african american (group a) or did not self-identify as black/african american (group b)
Descrizione

ethnic group

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0015031
participants have genotype 1 chc and laboratory evidence of hepatitis c virus (hcv) infection for at least 6 months
Descrizione

chronic hepatitis c; hepatitis c genotype

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0524910
UMLS CUI [2]
C1148363
participants did not achieve sustained viral response 24 weeks after last dose of study drug (svr24), after at least 1 prior course of peg-ifn-alfa-2a/rbv therapy of standard duration
Descrizione

dosage study drug

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0178602
UMLS CUI [1,2]
C0013227
UMLS CUI [1,3]
C0008972
Exclusion Criteria
Descrizione

Exclusion Criteria

Alias
UMLS CUI
C0680251
participants have received previous treatment with telaprevir or any other protease inhibitor(s) for chc
Descrizione

concomitant therapy telaprevir protease inhibitor

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C1707479
UMLS CUI [1,2]
C1876229
UMLS CUI [1,3]
C0033607
participants who have evidence of hepatic decompensation
Descrizione

hepatic decompensation

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0085605
participants have diagnosed or suspected hepatocellular carcinoma
Descrizione

hepatocellular carcinoma

Tipo di dati

boolean

Alias
UMLS CUI [1]
C2239176
participants have any other cause of significant liver disease in addition to hcv
Descrizione

liver disease

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0023895
participants are currently abusing illicit drugs or alcohol, or have history of illicit substance or alcohol abuse within 2 years before the screening visit
Descrizione

Substance Use Disorder

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0038586
participants who participated in any investigational drug study within 90 days before dosing
Descrizione

Study Subject Participation Status

Tipo di dati

boolean

Alias
UMLS CUI [1]
C2348568

Similar models

Eligibility Hepatitis C NCT01467492

Name
genere
Description | Question | Decode (Coded Value)
Tipo di dati
Alias
Item Group
C1512693 (UMLS CUI)
ethnic group
Item
participants self-identify as black/african american (group a) or did not self-identify as black/african american (group b)
boolean
C0015031 (UMLS CUI [1])
chronic hepatitis c; hepatitis c genotype
Item
participants have genotype 1 chc and laboratory evidence of hepatitis c virus (hcv) infection for at least 6 months
boolean
C0524910 (UMLS CUI [1])
C1148363 (UMLS CUI [2])
dosage study drug
Item
participants did not achieve sustained viral response 24 weeks after last dose of study drug (svr24), after at least 1 prior course of peg-ifn-alfa-2a/rbv therapy of standard duration
boolean
C0178602 (UMLS CUI [1,1])
C0013227 (UMLS CUI [1,2])
C0008972 (UMLS CUI [1,3])
Item Group
C0680251 (UMLS CUI)
concomitant therapy telaprevir protease inhibitor
Item
participants have received previous treatment with telaprevir or any other protease inhibitor(s) for chc
boolean
C1707479 (UMLS CUI [1,1])
C1876229 (UMLS CUI [1,2])
C0033607 (UMLS CUI [1,3])
hepatic decompensation
Item
participants who have evidence of hepatic decompensation
boolean
C0085605 (UMLS CUI [1])
hepatocellular carcinoma
Item
participants have diagnosed or suspected hepatocellular carcinoma
boolean
C2239176 (UMLS CUI [1])
liver disease
Item
participants have any other cause of significant liver disease in addition to hcv
boolean
C0023895 (UMLS CUI [1])
Substance Use Disorder
Item
participants are currently abusing illicit drugs or alcohol, or have history of illicit substance or alcohol abuse within 2 years before the screening visit
boolean
C0038586 (UMLS CUI [1])
Study Subject Participation Status
Item
participants who participated in any investigational drug study within 90 days before dosing
boolean
C2348568 (UMLS CUI [1])

Si prega di utilizzare questo modulo per feedback, domande e suggerimenti per miglioramenti.

I campi contrassegnati da * sono obbligatori.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial